Galapagos claimed that GLPG0492 is an orally available small molecule that has been developed in its Selective Androgen Receptor Modulator (SARM) program. The candidate drug has been shown to improve muscle mass in animal models.
With the support of Charley’s Fund and the Nash Avery Foundation Galapagos is currently evaluating the potential effectiveness of GLPG0492 in pre-clinical models of duchenne muscular dystrophy.
Galapagos said that the primary endpoints of this trial will be to determine the safety, tolerability and pharmacokinetics of the candidate drug GLPG0492. The double-blind, single ascending dose study is expected to be conducted in 16 healthy human volunteers in Belgium over the coming months, with results expected in the second half of 2010.
Onno van de Stolpe, CEO of Galapagos, said: “GLPG0492 is the fifth candidate drug to enter the clinic for Galapagos, since initiating our first clinical trial in March 2009.”